Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Editor's Note
This past week I was in our corporate offices and one of our District Managers came up to me and said he had developed type 1 diabetes. Although he is 42 years old, his physician had told him that his pancreas had quit working. His first indication was a loss of about 45 pounds over a 4 month period. He had started on an SGLT-2i and thought the weight loss was a result of that medication.
Now that he was on both long acting and mealtime insulin he did not understand why he should stay on the SGLT-2i. I shared my reasons and pointed him to an article that one of our interns had completed.
In this month’s SGLT-2i special edition we have that article for you, along with some other valuable items to review.
Dave Joffe
Editor-in-chief
Empagliflozin shows improvements in A1C while also having major adverse effects, but there could be a balance.
Can canagliflozin affect the progression of kidney disease in patients with type 2 diabetes?
Which antihyperglycemic agent will provide the greater cognitive benefit in patients who are elderly and have diabetes?
In part 1 of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT to lower risk of heart disease.
In part 4, the conclusion of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT2 to help prevent heart failure but not as a current treatment method.